GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Target validation of CD206 activators

$43,643
Anton Simeonov · National Center For Advancing Translational Sciences · ZIA · FY2019 · TR

Genotoxic effects of L1 retrotransposition trigger oocyte elimination during MPI

$43,576
Marla Elizabeth Tharp · Johns Hopkins University · F31 · FY2016 · HD

Cleavage of Bcl-xL by Caspases contributes to cell death in vivo

$43,576
Jason Huska · Johns Hopkins University · F31 · FY2016 · AI

Role of Acid in the Development of Barrett's Esophagus

$43,563
Rhonda F Souza · Ut Southwestern Medical Center · R01 · FY2010 · DK

Regulation of transendothelial migration of Tregs in irradiated HNSCCs by EphB4-ephrinB2 interaction

$43,552
Laurel B Darragh · University Of Colorado Denver · F31 · FY2022 · DE

Determining the spatial contexts that modulate immune cell phenotypes in colorectal cancer

$43,452
Jeremy D'silva · Stanford University · F31 · FY2025 · CA

KLRG1 as a novel target for immune checkpoint blockade

$43,410
Angela Tata · Brown University · F31 · FY2020 · CA

Gene and Virus Therapy Program

$43,374
Mitesh Borad · Mayo Clinic Rochester · P30 · FY2022 · CA

The roles of AP-1 pathway activation in NK cell development and exhaustion programming in AML

$43,287
Erin G. Jeremy · Ohio State University · F30 · FY2024 · CA

Improvement of cellular immunotherapy during dysbiosis - A. A. Brint Supplement

$43,275
Ruud P.m. Dings · Univ Of Arkansas For Med Scis · R01 · FY2024 · CA

Gene and Virus Therapy Program

$43,250
Mitesh Borad · Mayo Clinic Rochester · P30 · FY2023 · CA

Gene and Virus Therapy Program

$43,250
Mitesh Borad · Mayo Clinic Rochester · P30 · FY2021 · CA

Assessing TGF Beta1-Mediated ECM Remodeling in Metastatic Oral Squamous Cell Carcinoma

$43,072
John Aleman · University Of Colorado Denver · F31 · FY2022 · DE

The replication checkpoint and genomic fidelity in skin

$43,065
University Of Washington · K02 · FY2005 · AR

FOXA1 loss-of-function induces inflammatory cytokine signaling and immune suppression in prostate cancer

$42,907
Lourdes Brea · Northwestern University At Chicago · F31 · FY2023 · CA

Investigating mechanisms of pathogenesis and treatment response in immune checkpoint inhibitor induced colitis

$42,878
Jacqueline Mann · Yale University · F32 · FY2024 · CA

Regulation of transendothelial migration of Tregs in irradiated HNSCCs by EphB4-ephrinB2 interaction

$42,836
Laurel B Darragh · University Of Colorado Denver · F31 · FY2021 · DE

Program 30: Neuro-Oncology

$42,805
Charles Stiles · Dana-Farber Cancer Inst · P30 · FY2017 · CA

Thymic PD-1 blockade mediates the anti-tumor immune response in pediatric high-grade glioma

$42,691
Connor Patrick Francis · University Of Florida · F30 · FY2023 · CA

The use of epigenetic therapy to activate an immune response in ovarian cancer

$42,608
Katherine B Chiappinelli · Johns Hopkins University · F32 · FY2015 · CA

Protection of kidney from autoimmunity by modulating co-stimlatory signaling

$42,390
Naoka Murakami · Brigham And Women'S Hospital · K08 · FY2023 · DK

Targeting intracellular trafficking for cancer therapy

$42,358
Brendan Tyler Finicle · University Of California-Irvine · F99 · FY2021 · CA

Design and Delivery of Neoantigen-based Tumor Vaccines

$42,157
Christof Chiu Smith · Univ Of North Carolina Chapel Hill · F30 · FY2020 · CA

Program 12: Developmental Therapeutics

$42,116
Geoffrey I Shapiro · Dana-Farber Cancer Inst · P30 · FY2023 · CA

Program 12: Developmental Therapeutics

$42,116
Geoffrey I Shapiro · Dana-Farber Cancer Inst · P30 · FY2022 · CA